- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03908008
Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line
April 8, 2019 updated by: Medy-Tox
A Parallel, Active Drug Controlled, Double Blind, Randomized, Multi-center, Phase III Clinical Trial to Compare the Efficacy and Safety of MT10107 Versus BOTOX® in Treatment of Glabella Line
This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.
Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intramuscularly injected with the study drug or the comparator at a total of 20U (4U/0.1ml
each) in five sites of the glabella line.
Thereafter, follow-up visits will be made at 4 weeks, 10 weeks, 16 weeks and the efficacy and safety assessments will be conducted for a total of 16 weeks.
Study Type
Interventional
Enrollment (Actual)
136
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients attaining ≥grade 2(moderate) in the investigator's rating of the severity of glabella line at maximum frown
- Men and women aged between 20 and 65
- Patients who him/herself or him/her legal representatives voluntarily signed the informed consent
- Patients who can comply with the study procedures and visit schedule
Exclusion Criteria:
- Patients with general neuromuscular synaptic disorder(e.g. Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis)
- Patients who have bleeding tendency or taking anti-coagulant
- Patients suffering from acute diseases
- Patients who have been injected with botulinum toxin within past 3 months before the injection
- Patients with allergy or hypersensitivity to the investigational products or their components
- Patients who are pregnant or lactating or found to be pregnant through the urine or serum test or disagreed to avoid pregnancy during 16 weeks study period
- Patients who have been given any of the following drugs within previous 4 weeks at screening: Muscle relaxants, benzodiazepine, aminoglycoside antibiotics, other antibiotics, and anticholinergic drugs.
- Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis
- Patients with skin damage or infection at the injection site.
- Patients who scheduled a double eyelid operation during the clinical trial.
- Patients who have received or have a plan to receive other procedures, which may affect glabella and forehead lines within 6 months
- Patients whose glabella lines cannot be spread apart even with physical methods like using hands.
- Patients who are participating in other clinical trials or have participated in other clinical trials within 30 days of the screening date.
- Patients who are unable to communicate or follow the instructions
- Patients who are not eligible for this study at the discretion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Botox (Botulinum toxin type A)
20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line.
Treatment will be conducted just once in visit 2.
|
20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line.
Treatment will be conducted just once in visit 2.
20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line.
Treatment will be conducted just once in visit 2.
|
Experimental: MT10107 (Botulinum toxin type A)
20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line.
Treatment will be conducted just once in visit 2.
|
20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line.
Treatment will be conducted just once in visit 2.
20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line.
Treatment will be conducted just once in visit 2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator's live assessment of glabella line improvement rate
Time Frame: 4 weeks after the injection
|
Glabella line improvement rate determined by investigator's live assessment of glabella line severity at maximum frown at 4 weeks after the injection.
|
4 weeks after the injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator's live assessment of glabella line improvement rate
Time Frame: 10, 16 weeks after the injection
|
Glabella line improvement rate determined by investigator's live assessment of glabella line severity at maximum frown at 10, 16 weeks after the injection
|
10, 16 weeks after the injection
|
Investigator's live assessment of glabella line improvement rate
Time Frame: 4, 10, 16 weeks after the injection
|
Glabella line improvement rate determined by investigator's live assessment of glabella line severity at rest.
|
4, 10, 16 weeks after the injection
|
Investigator's photographic assessment of glabella line improvement rate at maximum frown
Time Frame: 4 weeks after the injection
|
Glabella line improvement rate determined by investigator's photographic assessment of glabella line severity at maximum frown at 4 weeks after the injection.
|
4 weeks after the injection
|
Investigator's photographic assessment of glabella line improvement rate at rest
Time Frame: 4 weeks after the injection
|
Glabella line improvement rate determined by investigator's photographic assessment of glabella line severity at rest.
|
4 weeks after the injection
|
Subject's satisfaction questionnaire to assess treatment efficacy
Time Frame: 4, 10, 16 weeks after the injection
|
Subject's satisfaction questionnaire from score 1 to 7, with 7 being the most satisfied, to assess the glabella line improvement at 4, 10, 16 weeks after the injection.
|
4, 10, 16 weeks after the injection
|
Glabella line improvement rate of subject's assessment
Time Frame: 4, 10, 16 weeks after the injection
|
Subject's assessment of glabella line improvement rate at 4, 10, 16 weeks after the injection.
|
4, 10, 16 weeks after the injection
|
The number of participants with adverse events determined by MedDra ver 17.0 for assessment of safety in IP
Time Frame: Through study completion, approximately 8 months
|
The number of participants with adverse events determined by MedDra ver 17.0 for assessment of safety in IP from the study start date to the end of study.
|
Through study completion, approximately 8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Huh Changhun, M.D., Seoul National University Bundang Hospital
- Principal Investigator: Yangwon Lee, M.D., Konkuk University Hospital
- Principal Investigator: Jonghee Lee, M.D., Samsung Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
November 18, 2014
First Submitted That Met QC Criteria
April 7, 2019
First Posted (Actual)
April 9, 2019
Study Record Updates
Last Update Posted (Actual)
April 10, 2019
Last Update Submitted That Met QC Criteria
April 8, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MT_PRT_GL03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glabellar Frown Lines
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedGlabellar Frown Lines | Frown LinesUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedGlabellar Frown Lines | Frown LinesUnited States
-
Galderma R&DCompletedGlabellar Frown Lines | Canthal LinesUnited States
-
ATGC Co., Ltd.RecruitingGlabellar Frown LinesKorea, Republic of
-
Medy-ToxCompletedGlabellar Frown LinesAustralia
-
Galderma R&DActive, not recruitingGlabellar Frown LinesUnited States
-
Galderma R&DCompletedGlabellar Frown LinesUnited States
-
Galderma R&DCompleted
-
Revance Therapeutics, Inc.CompletedEfficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar LinesGlabellar Frown LinesUnited States
-
Revance Therapeutics, Inc.CompletedGlabellar Frown LinesUnited States, Canada
Clinical Trials on Botox (Botulinum toxin type A)
-
Medy-ToxCompletedCervical Dystonia
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic CarcinomaUnited States
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Brazilan Center for Studies in DermatologyCompletedWrinkles in Frontal AreaBrazil
-
HugelCompletedOveractive BladderKorea, Republic of
-
HugelCompletedCervical DystoniaKorea, Republic of
-
Seton Healthcare FamilyCompleted